Merck's Keytruda shrinks lung cancer tumors, FDA approval sought
April 19, 2015 at 08:30 AM EDT
April 19 (Reuters) - Merck & Co Inc's Keytruda, approved for treating melanoma, was shown in a trial to shrink tumors in nearly half of advanced lung cancer patients with high levels of a protein used by tumors to evade the body's own disease-fighting cells.